Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Non-Current Assets (2018 - 2026)

Immunovant filings provide 8 years of Non-Current Assets readings, the most recent being $9.5 million for Q4 2025.

  • Quarterly Non-Current Assets rose 12.66% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.0 million through Dec 2025, up 106.13% year-over-year, with the annual reading at $8.5 million for FY2025, 1322.18% up from the prior year.
  • Non-Current Assets hit $9.5 million in Q4 2025 for Immunovant, roughly flat from $9.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $9.7 million in Q2 2025 and bottomed at $595000.0 in Q1 2024.
  • Average Non-Current Assets over 5 years is $4.0 million, with a median of $2.7 million recorded in 2021.
  • The largest annual shift saw Non-Current Assets tumbled 63.21% in 2023 before it skyrocketed 1433.6% in 2025.
  • Immunovant's Non-Current Assets stood at $2.7 million in 2021, then plummeted by 32.61% to $1.8 million in 2022, then tumbled by 63.21% to $670000.0 in 2023, then surged by 1152.39% to $8.4 million in 2024, then grew by 12.66% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Non-Current Assets are $9.5 million (Q4 2025), $9.4 million (Q3 2025), and $9.7 million (Q2 2025).